Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with placebo (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.44 [1.28, 1.63]
2 studies · 1556 participants
Moderate

Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.18 [1.09, 1.27]
1 study · 860 participants
Moderate